Y-Biologics

At a glance

Y-Biologics filed 69 disclosures in the last 12 months, including 20 insider and 9 5% holder. The most recent key filing was on Oct 20: CEO bought 6,375 sh on the market at an average ₩7,017, Oct 16–20.

Revenue for 2025 was ₩2.9B, down 49.5% on 2024. It made an operating loss of ₩9.3B. Debt was 110% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩1.8B and operating loss of ₩7.7B.

The 2025 annual report lists 58 employees with an average tenure of 4.5 years and average pay of ₩60.4M, #1124 of 2,191 listed companies by average pay. Its 5 directors and auditors were paid ₩180M each on average. It paid no cash dividend for 2025. 박영우 and related parties held 29.21% at year end.

Of 5 recent 5%+ holder reports, 4 raised and 1 cut a stake; the largest stake reported was 30.60% on Oct 1.

From the 2025 annual report

Staff: 58 (24 men, 34 women), of whom 2 on fixed-term contracts. Total pay for the year: ₩3.5B. Directors and auditors: 5, paid ₩901M in total.

No cash dividend was paid for 2025.

Largest shareholder

박영우 holds 23.17%; with 3 related parties the group holds 29.21% of common shares at year end (from 29.37% at the start of the year).

Auditor: 동성회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports